Inside Arbor’s CNS pipeline and next-generation gene editing

Episode 223

0:00-32:23

Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most, from ultra-rare liver diseases to conditions like ALS, where no truly effective treatments exist today. Arbor Biotechnologies is one of the companies pushing that frontier, built on a diverse toolbox of editing technologies that goes beyond the limitations of first-generation CRISPR tools. Its lead clinical program, ABO-101, targets PH1, and last October the company struck a partnership with Chiesi Group worth up to two billion dollars in milestones, with European regulators granting the program orphan drug designation just this summer. Arbor is also building out a CNS pipeline focused initially on ALS. Here to talk through the science, the strategy, and what's next is Devyn Smith, CEO of Arbor Biotechnologies. 01:36 – Meet Devyn Smith 07:48 – Arbor's toolbox approach versus single-editor CRISPR companies 12:16 – What PH1 is and how ABO-101 works 15:19 – Inside the Chiesi partnership for ABO-101 20:14 – Why ALS anchors Arbor's CNS pipeline 26:48 – Arbor's three-year outlook and long-term vision Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: What’s on the horizon for gene editing-based therapies?

Publisher

Beyond Biotech - the podcast from Labiotech

Published

November 13, 2026

Duration

32 min

Format

Podcast

Category

Issues · Tech News

Source

RSS feed

Host

Labiotech

BB

Beyond Biotech - the podcast from Labiotech

@beyondbiotechthepodcastfroml

#arborscnspipeline #generationgeneediting

The Nile